SCHEMBL4018480

SCHEMBL4018480

CCCn1c(-c2c[nH]nc2Cc2cccc(C(F)(F)F)c2)nc2c1c(=O)[nH]c(=O)n2CC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPH1 P17752 2/20 0.50
TPH2 Q8IWU9 2/20 0.50
KDM4E B2RXH2 7/20 0.44
ALDH1A1 P00352 7/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 6/20 0.44
KMT2A Q03164 6/20 0.44
POLB P06746 1/20 0.43
MAPT P10636 2/20 0.42
ADORA3 P0DMS8 3/20 0.42
ADORA2A P29274 3/20 0.42
ADORA2B P29275 3/20 0.42
ADORA1 P30542 2/20 0.42
PLK4 O00444 1/20 0.42
CDK2 P24941 1/20 0.42
IRAK1 P51617 1/20 0.42
RPS6KA3 P51812 1/20 0.42
PLK3 Q9H4B4 1/20 0.42
CSNK1G3 Q9Y6M4 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5061625 0.89 TPH1 (0.48) TPH1TPH2KDM4EALDH1A1MEN1
SCHEMBL4016921 0.86 ADORA2B (0.41) TPH1TPH2ADORA3ADORA2AADORA2B
SCHEMBL5509419 0.82 ADORA3 (0.44) TPH1TPH2KDM4EALDH1A1MEN1
SCHEMBL4291739 0.82 KDM1A (0.60) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL4284310 0.79 KDM1A (0.54) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL4295147 0.79 MAOB (0.40) TPH1TPH2SMN1; SMN2HTT
SCHEMBL4019325 0.78 LMNA (0.42) TPH1TPH2KDM4EALDH1A1HSD17B10
SCHEMBL1697135 0.78 ADORA2B (0.64) TPH1TPH2ADORA3ADORA2AADORA2B
SCHEMBL4016883 0.78 TPH1 (0.44) TPH1TPH2KDM4EALDH1A1HSD17B10
SCHEMBL3466169 0.78 ADORA2B (0.65) ADORA3ADORA2AADORA2BADORA1PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009157938-A1 A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING CANCER CV THERAPEUTICS, INC. (US) 2009-12-30 WO claimed
WO-2009088518-A1 A2B ADENOSINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER CV THERAPEUTICS, INC. (US) 2009-07-16 WO claimed
EP-1799221-A1 METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-06-27 EP claimed
JP-2007512335-A 2007-05-17 JP claimed
EP-1685132-A1 A sb 2B /sb ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-08-02 EP claimed
WO-2006044610-A1 METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC (US) 2006-04-27 WO claimed
WO-2005051951-A1 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-06-09 WO claimed
WO-2014153424-A1 REDUCING DIABETES IN PATIENTS RECEIVING HMG-COA REDUCTASE INHIBITORS (STATINS) LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) 2014-09-25 WO disclosed
WO-2009088518-A1 A2B ADENOSINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER CV THERAPEUTICS, INC. (US) 2009-07-16 WO disclosed